Background Greater height has been associated with increased risk of several cancers, but epidemiological data on height and pancreatic cancer are inconclusive. We conducted a systematic review and meta-analysis of prospective studies to clarify these results. Methods PubMed and several other databases were searched up to September 2011. Prospective studies of height and pancreatic cancer were included. Summary relative risks were estimated by the use of a random effects model. Results We identified twelve cohort studies that were included in the meta-analysis. The summary RR per 5-cm increase in height was 1.07 (95 % CI: 1.03-1.12, I 2 = 57 %). The results were similar among men and women. The summary estimate was attenuated when we included results from two pooled analyses together with these studies, summary RR = 1.03 (95 % CI: 1.00-1.07,
Introduction
Pancreatic cancer is the 9th most common cause of cancer with 277 000 new cases diagnosed in 2008 worldwide, accounting for about 2.2 % of all cancer cases [1] . There are few early symptoms of the disease and it is usually diagnosed in the later stages. Because of this, survival among pancreatic cancer patients is very low, on average only 6 months after the diagnosis [2] . Established risk factors include tobacco smoking, which explains about 20-25 % of pancreatic cancer cases [3, 4] , family history of pancreatic cancer [5] , pancreatitis [6] , diabetes (relative risk, RR = 1.8) [7] , and body fatness (RR = 1.10 per 5 kg/m 2 ) [8] . Tall people are at increased risk of several cancers [9, 10] , but the evidence relating height to pancreatic cancer risk is not convincing [9] . Both genetic and environmental factors determine adult attained height, which is partly a surrogate marker for in utero and childhood conditions [11] . Adult height is related to birth weight, rate of growth, and age of puberty and periods of peak growth, such as in infancy and adolescence, are particularly important in determining adult height [12] . Undernutrition and infectious diseases are the most important non-genetic factors affecting growth and adult body height, and as the prevalence of these conditions is reduced, an increase in height is observed [11] .
The World Cancer Research Fund/American Institute for Cancer Research report from 2007 stated that greater height was probably associated with increased risk of pancreatic cancer [9] ; however, studies published subsequent to this report have reported inconsistent results. The large European Prospective Investigation into Nutrition and Cancer reported a 74 % increase in pancreatic cancer risk comparing those with the highest with the lowest height [13] . However, other large studies [10, [14] [15] [16] [17] and three pooled analyses [18, 20] did not find a significant association between greater height and pancreatic cancer risk. To clarify these findings, we conducted a systematic review and dose-response meta-analysis of prospective cohort studies of adult height and pancreatic cancer risk. In particular, we wanted to clarify the dose-response relationship and explore potential heterogeneity by conducting subgroup and metaregression analyses.
Methods

Data sources and searches
The literature search and data extraction up to December 2005 was conducted by several reviewers at University of Leeds. Initially, several databases were searched including Pubmed, Embase, CAB Abstracts, ISI Web of Science, BIOSIS, LILACS, Cochrane library, CINAHL, AMED, National Research Register, and In Process Medline. Because all the relevant studies were identified through searches in PubMed, a change in the protocol was made, and only PubMed was used for the updated searches from January 2006 to September 2011. A predefined protocol was followed for the review (http://www.dietandcancer report.org/downloads/SLR_Manual.pdf) and includes details of the search terms (Supplemental appendix). Standard criteria for conducting and reporting meta-analyses were followed [21] . We also searched the reference lists of all the studies that were included in our analysis to identify any further studies.
Study selection
To be included, the study had to have a prospective cohort, case-cohort or nested case-control study design and to investigate the association between height and pancreatic cancer risk. Studies with a prospective design were included because they are less prone to selection bias than retrospective case-control studies. Estimates of the relative risk (hazard ratio, risk ratio) had to be available with the 95 % confidence intervals in the publication. For the doseresponse analysis, a quantitative measure of height had to be provided. We identified 20 possibly relevant publications in the search [10, [13] [14] [15] [16] [17] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . Two publications that only provided mean height among cases and controls were excluded [29, 32] , two duplicate publications were excluded [31, 33] , and one publication that did not provide any risk estimates was excluded [30] . Each study was only included once in the main analysis or in the subgroup analyses, but for some studies, overlapping publications provided results that were not available in the publication used for the main analysis, and these were used for some of the subgroup analyses. One of the remaining publications was only included in the subgroup analysis by gender [28] because a superseding publication (which was included in the overall analysis) only reported the results for men and women combined [15] , and two other publications [34, 35] were only included in the subgroup analysis of pancreatic cancer mortality as a publication from the same study with a larger number of cases was included in the overall analysis [15] .
Data extraction and quality assessment
The following data were extracted from each study: The first author's last name, publication year, country where the study was conducted, the study name, follow-up period, sample size, gender, age, number of cases, height assessment method (self-reported vs. measured), comparison of high versus low height in cm, RRs and 95 % CIs for the highest versus lowest level of height, and variables adjusted for in the analysis. The search and data extraction up to December 2005 was conducted by JEC, DSMC, VB, and several other reviewers at the University of Leeds. These 
Data synthesis and analysis
We used random effects models to calculate summary RRs and 95 % CIs for the highest versus the lowest height and for the dose-response analyses [36] . The average of the natural logarithm of the RRs was estimated, and the RR from each study was weighted by the inverse of its variance. A two-tailed p \ 0.05 was considered statistically significant. For the dose-response analyses, we used the method by Greenland and Longnecker [37] to compute study-specific slopes (linear trends) and 95 % CIs from the natural logs of the RRs and CIs across categories of height. The method requires that the distribution of cases and person-years or non-cases and the RRs with the variance estimates for at least three quantitative exposure categories are known. We estimated the distribution of cases or person-years in studies that did not report these, but reported the total number of cases/person-years, for example, the total number of personyears was divided by 5 when data were analyzed by quintiles in order to derive the number of person-years in each quintile. The Chêne and Thompson method was used to calculate the mean level of height in each category [38] . The dose-response results in the forest plots are presented for a 5-cm increment in height. We examined a potential nonlinear dose-response relationship by using fractional polynomial models [39] . The best-fitting second-order fractional polynomial regression model was determined, defined as the one with the lowest deviance. A likelihood ratio test was used to assess the difference between the nonlinear and linear models to test for nonlinearity [40] .
Heterogeneity between studies was assessed by the Q test and I 2 (a measure of the proportion of total variation in study estimates, which is due to heterogeneity) [41] . Subgroup and meta-regression analyses by sex, duration of follow-up, number of cases, geographic location, and adjustment for confounding factors such as alcohol, smoking, diabetes, body mass index, physical activity energy intake were conducted to investigate potential sources of heterogeneity. Small study effects, such as publication bias, was assessed by the inspection of the funnel plots and with Egger's test [42] and with Begg's test [43] , and the results were considered to indicate small study effects when p \ 0.10. We conducted sensitivity analyses excluding one study at a time to clarify whether the results were simply due to one large study or a study with an extreme result. In addition, results from three pooled analyses were included together with the identified studies in a sensitivity analysis [18] [19] [20] .
Results
We identified 12 cohort studies (15 publications) that were included in the analysis of height and pancreatic cancer risk [10, 13-17, 22-28, 34, 35] (Table 1, Fig. 1) . One of the publications were only included in subgroup analyses by sex [28] , and two were only included in the subgroup analysis of mortality [34, 35] . One publication reported the results from two cohort studies [24] . Seven studies were from Europe, four from North America, and one from South Korea (Table 1) .
Height
High versus low analysis
Eleven cohort studies (ten publications) [13] [14] [15] [16] [17] [23] [24] [25] [26] [27] were included in the high versus low analysis of height and pancreatic cancer risk and included 6178 cases among 3,076,365 participants. The summary RR for all studies was 1.21 (95 % CI: 1.07-1.36), with moderate heterogeneity, I 2 = 40 % and p heterogeneity = 0.08 (Fig. 2) .
Dose-response analysis
Ten cohort studies (eight publications) [10, 13-16, 22, 24, 25, 27] were included in the dose-response analysis and included 6,165 cases among 2,741,001 participants. The summary RR per 5-cm increase in height was 1.07 (95 % CI: 1.03-1.12), with moderate heterogeneity, I 2 = 57 % and p heterogeneity = 0.01 (Fig. 3) . The summary RR ranged from 1.06 (95 % CI: 1.02-1.10) when excluding the Nurses' Health Study to 1.08 (95 % CI: 1.04-1.13) when excluding the Women's Health Initiative. There was no indication of small study effects with either Egger's test, p = 0.15, or with Begg's test, p = 0.37. There was no evidence for a nonlinear association between height and pancreatic cancer risk, p nonlinearity = 0.14 ( Fig. 4) .
Subgroup, meta-regression, and sensitivity analyses
In subgroup analyses, the results were consistent when stratified by gender and geographic location and adjustment for confounding factors. Although not statistically significant, there was some indication of heterogeneity when stratified by number of cases (p heterogeneity = 0.10) with a weaker association among studies with a larger number of cases than among studies with a low number of cases (Table 2 ). Excluding one study of mortality [25] did not affect the results, summary RR = 1.08 (95 % CI: 1.03-1.13, I 2 = 61 %, p heterogeneity = 0.008) ( Table 2 ). Restricting the analysis to four studies of mortality [17, 25, [20] in our analysis (HR = 1.08, 95 % CI: 0.94-1.24 for men and HR = 0.99, 95 % CI: 0.82-1.21 for women per 6-cm increase in height), the summary RR was 1.06 (95 % CI: 1.03-1.10, I 2 = 50 %, p heterogeneity = 0.02) per 5-cm increase in height. When we included both these pooled analyses together with our analyses and excluding the overlapping studies, the summary RR was 1.03 (95 % CI: 1.00-1.07, I 2 = 44 %, p heterogeneity = 0.07) (Supplementary Figure 1) .
Discussion
We found a weak positive association between height and pancreatic cancer risk, which was of similar size among men and women, although only statistically significant among men.
Our meta-analysis may have several limitations that must be taken into consideration. The possibility of confounding from other risk factors cannot be ruled out. Although the results persisted in subgroup analyses of studies that adjusted for the most important confounding factors such as smoking, diabetes, and BMI, fewer studies had adjusted for other potential confounding factors. Although there was no evidence of small study effects with the statistical tests in our analysis, it is still possible that a number of studies with null results have remained unpublished, and this could have led to exaggerated risk estimates. Our results are in contrast to those of three pooled analyses [18] [19] [20] , which found no significant association between height and pancreatic cancer risk, but included more than twice as many cases and more than three times as many participants as the two largest of these [18, 19] . Although some of the studies included in our analysis overlapped with some of the pooled analyses [13, 14, 16, 24] , several cohort studies [10, 15, 22, 23, 25] not included in the pooled analyses may have driven the overall result toward an increased risk in our analysis. However, a number of the studies included in the pooling projects have not yet published on height and pancreatic cancer individually. In several sensitivity analyses, we added the pooled results of the Pooling Project of Prospective Studies [18] and the Asian Pacific Cohort Studies Collaboration [20] to the dose-response analyses, and although the results were attenuated, there was still a significant positive association. This suggests that the summary estimate from our primary analysis may have been overestimated, but may not entirely be due to publication bias. Publication bias may have occurred because several of the individual studies contributing to the pooled analyses may have had moderate sample sizes and possibly insufficient statistical power to detect an association with a relatively uncommon cancer such as pancreatic cancer. In addition, it may not have been a priority in more modest sized cohorts to investigate a non-modifiable risk factor for pancreatic cancer.
In the overall analysis, there was moderate heterogeneity. We did not find an explanation for this heterogeneity as it persisted in most subgroup analyses, and there was also no significant heterogeneity between subgroups when we conducted meta-regression analyses. There was a suggestion of a weaker effect in larger studies; however, this difference did not reach statistical significance either (p heterogeneity = 0.10).
Measurement errors in the assessment of height may have influenced the results. Several studies have reported high correlations between measured and self-reported height [44] [45] [46] . The association between height and pancreatic cancer risk was only observed in studies that used self-reported height and not in studies where height was measured; however, the few studies in these subgroup analyses and the lack of heterogeneity between these subgroups make the interpretation of the results difficult.
Although increased height is an established risk factor for colorectal and breast cancer and a possible risk factor for several other cancers [9, 10] , the specific mechanism(s) that may explain an association between greater height and pancreatic cancer risk is not clear. It is also possible that common mechanisms may underlie the association between height and several cancers including pancreatic cancer. Adult height reaches its maximum between age 20 and 30 years, and both childhood and adolescent dietary factors and infections are thought to be of importance [47, 48] . Particularly, elevated levels of insulin-like growth factor-1 (IGF-1) may play an important role in determining growth and may also influence cancer risk. Higher IGF-1 levels in childhood is associated with childhood growth [49] . Insulin-like growth factors may contribute to cancer risk by stimulating proliferation, adhesion, and cell migration and by inhibiting apoptosis [50] . However, greater concentrations of circulating IGF-1 in adulthood has not been significantly associated with pancreatic cancer risk in epidemiological studies [32, [51] [52] [53] , but if the relevant time period of exposure is in childhood n denotes the number of studies, a p for heterogeneity within each subgroup, b p for heterogeneity between subgroups with meta-regression analysis. * p for heterogeneity between men and women or adolescence, this could explain the lack of association reported in these studies. At last, taller people have a greater number of cells, and thus a greater probability of mutations leading to malignancy.
Our meta-analysis also has several strengths. Because we based our analyses on prospective studies, we have effectively avoided recall bias and reduced the possibility for selection bias. The large sample size and large number of cases provided statistical power to detect moderate associations. In addition, we conducted more detailed subgroup and sensitivity analyses than what has been done previously, and we assessed the dose-response relationship using both linear and nonlinear models. In sensitivity analyses, we included the results of pooled analyses to increase the number of cohort studies contributing information. We have therefore obtained a more precise estimate than in the primary analyses. However, it has to be noted that including pooled results does not allow to properly assess heterogeneity. Nevertheless, the one pooled analysis that reported on heterogeneity found no evidence of heterogeneity across studies, so this should be less of a concern [18] .
In conclusion, our results indicate that greater height is associated with increased risk of pancreatic cancer. However, given the unexplained heterogeneity, further studies are needed before a conclusion can be drawn.
